Interim Results of The Medicines Company’s ORION-3 Study of Inclisiran Presented at National Lipid Association Scientific Sessions
Interim results from the ongoing ORION-3 study that examines the long-term safety and efficacy of small interfering RNA (siRNA) therapy drug inclisiran were shared today during the National Lipid Association’s (NLA) 2019 Scientific Sessions late-breaking abstract session.
Inclisiran, the first cholesterol-lowering therapy in the siRNA class, has the potential to deliver consistent lowering of LDL cholesterol through twice-a-year dosing.
Among the results presented today:
- Primary endpoint at ~22 months from baseline showed 51% lower LDL-C (p-value <0.001)
- Time-averaged lowering of LDL-C in ORION-3 was ~60 mg/dL
- The medication was well tolerated and there was no Rx-related elevation of liver enzymes or changes in renal function
To access the full results of the study, view the slide deck here